Cited by 541Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Clearing the brain's amyloid cobwebs

Open access
Selkoe, Dennis J.·2001·Neuron

Abstract

Elevated cerebral levels of amyloid beta-protein occur universally in Alzheimer's disease, yet only a few patients show evidence of increased Abeta production. Therefore, defects in proteases that degrade Abeta could underlie some or many cases of familial and sporadic AD. This previously neglected topic has begun receiving serious attention. Understanding how proteolysis regulates Abeta levels in the cerebral cortex has implications for both the pathogenesis and the treatment of this protean disorder.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0896-6273(01)00475-5

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Defects in the clearance of brain Aβ by cellular uptake or transport across the blood-brain barrier might underlie many cases of sporadic AD.

    “Defects in the clearance of brain Aβ by cellular uptake or transport across the blood-brain barrier might underlie many cases of sporadic AD (Selkoe, 2001; Zlokovic, 2008).”

    From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Selkoe, 2001

    The passage labeled Abstract (page unavailable) says faulty Aβ clearance may cause many, perhaps most, AD cases, supporting the claim’s general possibility. The paper discusses microglial removal and transport of Aβ-antibody complexes out of the brain in the context of immunization, but it does not link defects in cellular uptake or blood-brain-barrier transport specifically to many sporadic AD cases. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 9

  1. [1]1. Backstrom, J.R. ∙ Lim, G.P. ∙ Cullen, M.J. ... J. Neurosci. 1996; 16:7910-7919 Crossref PubMed Google Scholar
  2. [2]2. Bard, F. ∙ Cannon, C. ∙ Barbour, R. ... Nat. Med. 2000; 6:916-919 Crossref Scopus (1865) PubMed Google Scholar
  3. [3]3. Bennett, R.G. ∙ Duckworth, W.C. ∙ Hamel, F.G. J. Biol. Chem. 2000; 275:36621-36625 Crossref Scopus (145) PubMed Google Scholar
  4. [5]5. Eckman, E.A. ∙ Reed, D.K. ∙ Eckman, C.B. J. Biol. Chem. 2001; 276:24540-24548 Crossref Scopus (296) PubMed Google Scholar
  5. [6]6. Fakhrai-Rad, H. ∙ Nikoshkov, A. ∙ Kamel, A. ... Hum. Mol. Genet. 2000; 9:2149-2158 Crossref Scopus (139) PubMed Google Scholar
  6. [7]7. Howell, S. ∙ Nalbantoglu, J. ∙ Crine, P. Peptides. 1995; 16:647-652 Crossref Scopus (189) PubMed Google Scholar
  7. [8]8. Iwata, N. ∙ Tsubuki, S. ∙ Takaki, Y. ... Nat. Med. 2000; 6:143-150 Crossref Scopus (0) PubMed Google Scholar
  8. [9]9. Iwata, N. ∙ Tsubuki, S. ∙ Takaki, Y. ... Science. 2001; 292:1550-1552 Crossref Scopus (874) PubMed Google Scholar
  9. [10]10. Kurochkin, I.V. ∙ Goto, S. FEBS Lett. 1994; 345:33-37

Cited by

Sorted by citations

Authors
Selkoe, D. J.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Selkoe, Dennis J.
Venue
Neuron
Publisher
Elsevier BV
Published
2001-10
Volume
32
Issue
2
Pages
177-180
ISSN
0896-6273 (ISSN-L)
OpenAlex
W2072435649
Cited by
541
References
3
Citations by year
2026: 2 · 2025: 8 · 2024: 9 · 2023: 9 · 2022: 11 · 2021: 10 · 2020: 9 · 2019: 15 · 2018: 24 · 2017: 16 · 2016: 23 · 2015: 16 · 2014: 18 · 2013: 25 · 2012: 25
FWCI
16.76
Type
journal article
Language
en
Open access
Locations
  • Neuron (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid-beta, Alzheimer's disease, proteolytic enzymes, proteolysis, amyloid clearance, cerebral cortex, familial Alzheimer's disease, sporadic Alzheimer's disease, pathogenesis, treatment
MeSH terms
Alzheimer Disease, Animals, Brain, Humans, Insulysin, Mutation, Endopeptidases, Neprilysin, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review